Belviq partners up with phentermine

Share this article:

Eisai's experiment with Belviq add-on weight-loss therapy is underway. MedPage Today reports that the two-part medication includes relative weight-loss newcomer Belviq with the older appetite suppressant phentermine, which was part of the disastrous combination weight-loss drug Fen-phen.

Despite the negative connotation, MedPage says the trial mix has been dubbed Belphen. The 12-week trial started in October and was sponsored by drug partners Arena and Eisai.

MedPage says the 225-patient study is a safety trial, and that the impact on weight loss and waist circumference are secondary endpoints. The study does not include a placebo group, nor does it include a echocardiogram, because Belviq's cardiovascular safety profile was sufficient for FDA approval.

The majority of experts told MedPage that they were OK with this study's lack of a cardiovascular component—phentermine was not considered the reason for Fen-Phen's heart damage. However, not everyone is sure this is the smartest way to go.

“This... looks a lot like an opportunity to repeat the dangerous follies of history,” Yale University's Prevention Research Center's David Katz told MedPage.

Share this article:

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.